188 related articles for article (PubMed ID: 24206093)
1. Inhibition of type I insulin-like growth factor receptor tyrosine kinase by picropodophyllin induces apoptosis and cell cycle arrest in T lymphoblastic leukemia/lymphoma.
Huang Z; Fang Z; Zhen H; Zhou L; Amin HM; Shi P
Leuk Lymphoma; 2014 Aug; 55(8):1876-83. PubMed ID: 24206093
[TBL] [Abstract][Full Text] [Related]
2. Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.
Vishwamitra D; Shi P; Wilson D; Manshouri R; Vega F; Schlette EJ; Amin HM
Haematologica; 2011 Jun; 96(6):871-80. PubMed ID: 21330319
[TBL] [Abstract][Full Text] [Related]
3. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
[TBL] [Abstract][Full Text] [Related]
4. Picropodophyllin inhibits type I endometrial cancer cell proliferation via disruption of the PI3K/Akt pathway.
Dong L; Du M; Lv Q
Acta Biochim Biophys Sin (Shanghai); 2019 Jul; 51(7):753-760. PubMed ID: 31168597
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.
Duan Z; Choy E; Harmon D; Yang C; Ryu K; Schwab J; Mankin H; Hornicek FJ
Mol Cancer Ther; 2009 Aug; 8(8):2122-30. PubMed ID: 19638450
[TBL] [Abstract][Full Text] [Related]
6. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells.
Strömberg T; Ekman S; Girnita L; Dimberg LY; Larsson O; Axelson M; Lennartsson J; Hellman U; Carlson K; Osterborg A; Vanderkerken K; Nilsson K; Jernberg-Wiklund H
Blood; 2006 Jan; 107(2):669-78. PubMed ID: 16166596
[TBL] [Abstract][Full Text] [Related]
7. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.
Wang Q; Wei F; Lv G; Li C; Liu T; Hadjipanayis CG; Zhang G; Hao C; Bellail AC
BMC Cancer; 2013 Nov; 13():521. PubMed ID: 24182354
[TBL] [Abstract][Full Text] [Related]
8. Alternative cytotoxic effects of the postulated IGF-IR inhibitor picropodophyllin in vitro.
Wu X; Sooman L; Wickström M; Fryknäs M; Dyrager C; Lennartsson J; Gullbo J
Mol Cancer Ther; 2013 Aug; 12(8):1526-36. PubMed ID: 23699657
[TBL] [Abstract][Full Text] [Related]
9. The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling.
Razuvaev A; Henderson B; Girnita L; Larsson O; Axelson M; Hedin U; Roy J
J Vasc Surg; 2007 Jul; 46(1):108-15. PubMed ID: 17606126
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor type-I receptor-dependent phosphorylation of extracellular signal-regulated kinase 1/2 but not Akt (protein kinase B) can be induced by picropodophyllin.
Vasilcanu R; Vasilcanu D; Sehat B; Yin S; Girnita A; Axelson M; Girnita L
Mol Pharmacol; 2008 Mar; 73(3):930-9. PubMed ID: 18070930
[TBL] [Abstract][Full Text] [Related]
11. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway.
Vasilcanu D; Girnita A; Girnita L; Vasilcanu R; Axelson M; Larsson O
Oncogene; 2004 Oct; 23(47):7854-62. PubMed ID: 15334055
[TBL] [Abstract][Full Text] [Related]
12. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
13. Picropodophyllin inhibits tumor growth of human nasopharyngeal carcinoma in a mouse model.
Yin SC; Guo W; Tao ZZ
Biochem Biophys Res Commun; 2013 Sep; 439(1):1-5. PubMed ID: 23973483
[TBL] [Abstract][Full Text] [Related]
14. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1.
Vasilcanu R; Vasilcanu D; Rosengren L; Natalishvili N; Sehat B; Yin S; Girnita A; Axelson M; Girnita L; Larsson O
Oncogene; 2008 Mar; 27(11):1629-38. PubMed ID: 17828296
[TBL] [Abstract][Full Text] [Related]
15. Targeting the insulin-like growth factor-1 receptor by picropodophyllin for lung cancer chemoprevention.
Zhang Q; Pan J; Lubet RA; Wang Y; You M
Mol Carcinog; 2015 Jun; 54 Suppl 1():E129-37. PubMed ID: 25163779
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK
George B; George SK; Shi W; Haque A; Shi P; Eskandari G; Axelson M; Larsson O; Kaseb AO; Amin HM
J Hematol Oncol; 2019 Jul; 12(1):80. PubMed ID: 31340850
[TBL] [Abstract][Full Text] [Related]
17. The insulin-like growth factor-I receptor inhibitor picropodophyllin-induced selective apoptosis of hepatocellular carcinoma cell through a caspase-dependent mitochondrial pathway.
E C; Li J; Shao D; Zhang D; Pan Y; Chen L; Zhang X
Oncol Res; 2013; 21(2):103-10. PubMed ID: 24406046
[TBL] [Abstract][Full Text] [Related]
18. Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma.
Karasic TB; Hei TK; Ivanov VN
Exp Cell Res; 2010 Jul; 316(12):1994-2007. PubMed ID: 20417200
[TBL] [Abstract][Full Text] [Related]
19. The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllin.
Lemaire M; Fristedt C; Agarwal P; Menu E; Van Valckenborgh E; De Bruyne E; Österborg A; Atadja P; Larsson O; Axelson M; Van Camp B; Jernberg-Wiklund H; Vanderkerken K
Clin Cancer Res; 2012 Apr; 18(8):2230-9. PubMed ID: 22392915
[TBL] [Abstract][Full Text] [Related]
20. Picropodophyllin causes mitotic arrest and catastrophe by depolymerizing microtubules via insulin-like growth factor-1 receptor-independent mechanism.
Waraky A; Akopyan K; Parrow V; Strömberg T; Axelson M; Abrahmsén L; Lindqvist A; Larsson O; Aleem E
Oncotarget; 2014 Sep; 5(18):8379-92. PubMed ID: 25268741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
